BIOGEN INC.
BIIBNasdaq · SIC 2836
$205.99
↓ -1.4%Jul 17 close · end-of-day
Price
1Y↑ +60.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$30.6B
Enterprise Value
$36.0B
P/E
22.1
P/S
3.1
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
7.9%
Dividend Yield
—
Revenue (TTM)
$9.9B
Net Income (TTM)
$1.4B
Free Cash Flow (TTM)
$2.4B
Gross Margin
—
Operating Margin
—
Net Margin
13.8%
ROE
7.4%
ROIC
—
Debt / Equity
0.3
Net Cash
-$5.4B
Return 1Y
+60.1%
Company profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. It also offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and pemphigus vulgaris.
- CEO
- Christopher A. Viehbacher
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 8,720
- Headquarters
- Massachusetts
- Website
- biogen.com
Management & directors
- Keeney AdamHead of Corporate Development
- Godbout SeanChief Accounting Officer
- Murphy NicoleHead of Pharm Ops and Tech
- Singhal PriyaHead of Development
- Alexander Susan HEVP Chief Legal Officer
- Gregory GingerEVP, Human Resources
- Grogan JaneHead of Research
- Izzar RachidHead of Global Product Strat.
- Kramer RobinChief Financial Officer
- Viehbacher ChristopherPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-09-30
BIIB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.5B↑ +1.9%
Diluted EPS$2.15↑ +31.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.4B | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B |
| Gross profit | $11.6B | — | — | — | — | — |
| Operating income | $4.6B | $2.8B | — | — | — | — |
| Net income | $4.0B | $1.6B | $3.0B | $1.2B | $1.6B | $1.3B |
| Diluted EPS | $24.80 | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Operating cash flow | $4.2B | $3.6B | $1.4B | $1.5B | $2.9B | $2.2B |
| Free cash flow | $3.8B | $3.4B | $1.1B | $1.3B | $2.7B | $2.1B |
| Gross margin | 86.6% | — | — | — | — | — |
| Operating margin | 33.8% | 25.9% | — | — | — | — |
| Net margin | 29.8% | 14.2% | 30.0% | 11.8% | 16.9% | 13.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.5B | $2.5B | $2.4B | $2.6B | $2.5B | $2.3B | $2.5B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $583.6M | $388.5M | $266.5M | $240.5M | $634.8M | $466.5M | -$48.8M | $319.5M |
| Diluted EPS | $4.00 | $2.66 | $1.82 | $1.64 | $4.33 | $3.17 | -$0.35 | $2.15 |
| Operating cash flow | $625.8M | $935.6M | $760.9M | $259.3M | $160.9M | $1.3B | $511.9M | $645.5M |
| Free cash flow | $592.3M | $900.6M | $721.6M | $222.2M | $134.3M | $1.2B | $468.0M | $594.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | 23.7% | 15.8% | 10.9% | 9.9% | 24.0% | 18.4% | -2.1% | 12.9% |
Company news
Jul 20, 2026
Jul 16, 2026
Jul 15, 2026
- 5d ago3 Reasons to Avoid BIIB and 1 Stock to Buy Insteadfinance.yahoo.com
- 5d agoBiogen Shares Decline After Detailed Diranersen Alzheimer's Study Datafinance.yahoo.com
- 5d agoBiogen Appoints Michael J. Parini as Chief Legal Officerfinance.yahoo.com
- 5d agoAAIC26: Biogen stock drops after unveiling tau-targeting ASO dataclinicaltrialsarena.com
- 5d agoBiogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intactfinance.yahoo.com
Jul 14, 2026
- 5d agoIBM, Goldman Sachs, SK Hynix, Micron, CrowdStrike, Biogen, and More Stocks That Explain Today’s Marketfinance.yahoo.com
- 5d agoBiogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'finance.yahoo.com
- 6d agoBiogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Missmarketbeat.com
- 6d agoBIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Studystocktwits.com
- 6d agoBiogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problemfinance.yahoo.com
- 6d agoBiogen stock falls 8% on Alzheimer's drug diranersen trial dataqz.com
- 6d agoBiogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembifinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-09 | Patolawala Monish D | Award | 1,505 | $0.00 | $0.00 | filing |
| 2026-06-09 | Rowinsky Eric K | Award | 1,505 | $0.00 | $0.00 | filing |
| 2026-06-09 | Mantas Jesus B | Award | 1,505 | $0.00 | $0.00 | filing |
| 2026-06-09 | Pangalos Menelas N | Award | 1,505 | $0.00 | $0.00 | filing |
| 2026-06-09 | Freire Maria C | Award | 2,005 | $0.00 | $0.00 | filing |
| 2026-06-09 | Pangalos Menelas N | Option exercise | 2,370 | $0.00 | $0.00 | filing |
| 2026-06-09 | HAWKINS WILLIAM A | Award | 1,505 | $0.00 | $0.00 | filing |
| 2026-06-09 | Minor Lloyd | Award | 1,505 | $0.00 | $0.00 | filing |
| 2026-06-09 | LANGER SUSAN | Award | 1,505 | $0.00 | $0.00 | filing |
| 2026-06-09 | SHERWIN STEPHEN A | Award | 1,505 | $0.00 | $0.00 | filing |
| 2026-05-01 | Keeney Adam· Head of Corporate Development | Tax withholding | 455 | $187.06 | $85,112.30 | filing |
| 2026-05-01 | Keeney Adam· Head of Corporate Development | Option exercise | 939 | $0.00 | $0.00 | filing |
| 2026-04-01 | Godbout Sean· Chief Accounting Officer | Tax withholding | 54 | $183.78 | $9,924.12 | filing |
| 2026-04-01 | Godbout Sean· Chief Accounting Officer | Option exercise | 181 | $0.00 | $0.00 | filing |
| 2026-02-12 | Murphy Nicole· Head of Pharm Ops and Tech | Buy | 3 | $195.04 | $585.11 | filing |
| 2026-02-09 | Singhal Priya· Head of Development | Sale | 2,660 | $199.83 | $531,547.80 | filing |
| 2026-02-06 | Viehbacher Christopher· President and CEO | Tax withholding | 6,624 | $201.18 | $1.3M | filing |
| 2026-02-06 | Viehbacher Christopher· President and CEO | Tax withholding | 4,356 | $201.18 | $876,340.08 | filing |
| 2026-02-06 | ALEXANDER SUSAN H· EVP Chief Legal Officer | Tax withholding | 1,514 | $201.18 | $304,586.52 | filing |
| 2026-02-06 | Singhal Priya· Head of Development | Tax withholding | 1,412 | $201.18 | $284,066.16 | filing |
| 2026-02-06 | Murphy Nicole· Head of Pharm Ops and Tech | Tax withholding | 1,408 | $201.18 | $283,261.44 | filing |
| 2026-02-06 | Gregory Ginger· EVP, Human Resources | Tax withholding | 1,132 | $201.18 | $227,735.76 | filing |
| 2026-02-06 | Kramer Robin· Chief Financial Officer | Tax withholding | 1,063 | $201.18 | $213,854.34 | filing |
| 2026-02-06 | ALEXANDER SUSAN H· EVP Chief Legal Officer | Tax withholding | 1,059 | $201.18 | $213,049.62 | filing |
| 2026-02-06 | Singhal Priya· Head of Development | Tax withholding | 1,056 | $201.18 | $212,446.08 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.